Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “hold” rating restated by equities researchers at JPMorgan Chase & Co. in a research note issued on Tuesday, AnalystRatings.com reports.
Other research analysts have also recently issued research reports about the stock. TheStreet raised shares of Regeneron Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Monday, December 2nd. Piper Jaffray Companies set a $435.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, October 8th. SunTrust Banks assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, November 12th. They issued a “hold” rating and a $360.00 target price on the stock. BMO Capital Markets upped their target price on shares of Regeneron Pharmaceuticals from $344.00 to $358.00 and gave the company a “market perform” rating in a research report on Wednesday, November 6th. Finally, Bank of America initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 16th. They set a “neutral” rating and a $325.00 price target on the stock. Thirteen investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $387.89.
NASDAQ REGN traded down $6.71 during trading hours on Tuesday, reaching $384.31. The company had a trading volume of 10,406 shares, compared to its average volume of 540,260. The stock has a 50-day moving average of $374.08 and a 200 day moving average of $321.51. Regeneron Pharmaceuticals has a 1-year low of $271.37 and a 1-year high of $442.00. The company has a current ratio of 4.03, a quick ratio of 3.27 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $42.90 billion, a P/E ratio of 19.42, a price-to-earnings-growth ratio of 1.07 and a beta of 1.20.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, November 5th. The biopharmaceutical company reported $6.67 EPS for the quarter, beating the Zacks’ consensus estimate of $5.13 by $1.54. Regeneron Pharmaceuticals had a net margin of 28.13% and a return on equity of 24.85%. The company had revenue of $2.05 billion for the quarter, compared to analysts’ expectations of $1.98 billion. During the same quarter in the prior year, the company posted $5.87 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, sell-side analysts predict that Regeneron Pharmaceuticals will post 20.26 EPS for the current year.
Regeneron Pharmaceuticals declared that its Board of Directors has initiated a share repurchase program on Tuesday, November 5th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to purchase up to 2.9% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.
In other news, Chairman P Roy Vagelos sold 22,149 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $363.83, for a total transaction of $8,058,470.67. Also, EVP Neil Stahl sold 7,364 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $338.52, for a total transaction of $2,492,861.28. Following the transaction, the executive vice president now owns 21,150 shares in the company, valued at $7,159,698. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 109,543 shares of company stock worth $40,357,770. Insiders own 11.84% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in REGN. Vanguard Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 0.9% during the second quarter. Vanguard Group Inc. now owns 6,079,347 shares of the biopharmaceutical company’s stock worth $1,902,835,000 after purchasing an additional 54,247 shares during the period. State Street Corp lifted its holdings in shares of Regeneron Pharmaceuticals by 1.6% during the third quarter. State Street Corp now owns 3,529,859 shares of the biopharmaceutical company’s stock worth $979,183,000 after purchasing an additional 57,027 shares during the period. Invesco Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 3.5% during the second quarter. Invesco Ltd. now owns 1,344,273 shares of the biopharmaceutical company’s stock worth $420,759,000 after purchasing an additional 46,055 shares during the period. Pictet Asset Management Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 11.7% during the third quarter. Pictet Asset Management Ltd. now owns 601,284 shares of the biopharmaceutical company’s stock worth $166,796,000 after purchasing an additional 62,926 shares during the period. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $151,443,000. Institutional investors and hedge funds own 66.42% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: Most Volatile Stocks
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.